OSR (NASDAQ:OSRH – Get Free Report) is one of 89 public companies in the “UNCLASSIFIED” industry, but how does it compare to its peers? We will compare OSR to related businesses based on the strength of its risk, dividends, analyst recommendations, earnings, valuation, institutional ownership and profitability.
Profitability
This table compares OSR and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OSR | N/A | -12.19% | -8.18% |
| OSR Competitors | 0.86% | 0.95% | 0.80% |
Earnings and Valuation
This table compares OSR and its peers revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| OSR | N/A | -$2.41 million | -0.59 |
| OSR Competitors | $40.24 million | -$18.54 million | 92.80 |
Risk and Volatility
OSR has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. Comparatively, OSR’s peers have a beta of -0.08, meaning that their average stock price is 108% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations and price targets for OSR and its peers, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OSR | 1 | 0 | 0 | 0 | 1.00 |
| OSR Competitors | 217 | 264 | 217 | 3 | 2.01 |
As a group, “UNCLASSIFIED” companies have a potential upside of 52.68%. Given OSR’s peers stronger consensus rating and higher probable upside, analysts plainly believe OSR has less favorable growth aspects than its peers.
Institutional and Insider Ownership
55.3% of OSR shares are owned by institutional investors. Comparatively, 51.0% of shares of all “UNCLASSIFIED” companies are owned by institutional investors. 60.6% of OSR shares are owned by company insiders. Comparatively, 41.8% of shares of all “UNCLASSIFIED” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
OSR peers beat OSR on 9 of the 13 factors compared.
OSR Company Profile
OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.
Receive News & Ratings for OSR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OSR and related companies with MarketBeat.com's FREE daily email newsletter.
